Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 543.65M P/E - EPS this Y 40.80% Ern Qtrly Grth -
Income -208.38M Forward P/E -3.73 EPS next Y 16.90% 50D Avg Chg 12.00%
Sales 1.7M PEG - EPS past 5Y - 200D Avg Chg 36.00%
Dividend N/A Price/Book 2.03 EPS next 5Y - 52W High Chg -17.00%
Recommedations 1.80 Quick Ratio 5.90 Shares Outstanding 265.93M 52W Low Chg 96.00%
Insider Own 18.04% ROA -25.35% Shares Float 107.56M Beta 2.03
Inst Own 75.01% ROE -101.61% Shares Shorted/Prior 3.52M/4.17M Price 3.13
Gross Margin - Profit Margin - Avg. Volume 730,825 Target Price 10.69
Oper. Margin -10,337.34% Earnings Date May 17 Volume 386,508 Change -0.63%
About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc News
06:00 AM Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
05/14/24 Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
05/13/24 Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
04/25/24 Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year
04/24/24 Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
04/23/24 Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
04/02/24 Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
04/01/24 Autolus Therapeutics Announces Changes to its Board of Directors
03/21/24 Q4 2023 BioNTech SE Earnings Call
08:19 AM Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript
03/15/24 Autolus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
03/15/24 Q4 2023 Autolus Therapeutics PLC Earnings Call
03/14/24 Autolus Therapeutics PLC Reports Full Year 2023 Financial Results
03/14/24 Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
03/12/24 Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
03/11/24 Autolus Therapeutics announces publication in Blood Cancer Journal
02/29/24 Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
02/22/24 Autolus Therapeutics announces publication in Nature Communications
02/21/24 Autolus Therapeutics plc's (NASDAQ:AUTL) institutional investors lost 8.1% last week but have benefitted from longer-term gains
02/15/24 Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
AUTL Chatroom

User Image 5556_peacock Posted - 3 hours ago

$AUTL READ THE GRAPH :

User Image 5556_peacock Posted - 3 hours ago

$AUTL LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 13-16, 2024. PDUFA Date expected November 16, 2024. Phase 2 longer-term data to be presented at ASCO 2024, abstract to be released May 23, with a presentation on May 31, 2024. Data to be presented at EHA on June 14, 2024.

User Image _www_larval_com_ Posted - 5 hours ago

$UK 10%[11%] $ASTS -5%[7%] $CRNC -4%[-10%] $GME -4%[-25%] $AUTL -4%[11%] most notable movement within the first minutes of trading.

User Image SouthernItUp Posted - 6 hours ago

$AUTL .

User Image SouthernItUp Posted - 6 hours ago

$AUTL

User Image Mancunian Posted - 7 hours ago

$AUTL Todays results confirm that all is on track and that Autolus will become a World leader in its field…

User Image DonCorleone77 Posted - 7 hours ago

$AUTL Autolus Therapeutics reports Q1 EPS (24c), consensus (5c) Reports Q1 revenue $10.091M vs $1.292M last year. "We continue to engage with the FDA in the regulatory review process for obecabtagene autoleucel in adult ALL as we head towards the PDUFA target action date of November 16, 2024, and are driving commercial readiness activities across the Company," said Dr. Christian Itin, Chief Executive Officer of Autolus. "We're also delighted that our abstracts from the pivotal FELIX Phase 2 trial have been accepted for oral presentations at ASCO and EHA this year and we look forward to sharing further long-term data and additional subset analyses."

User Image Stock_Titan Posted - 7 hours ago

$AUTL Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates https://www.stocktitan.net/news/AUTL/autolus-therapeutics-reports-first-quarter-2024-financial-results-3nar9gkkmy39.html

User Image BullRush247 Posted - 19 hours ago

$AUTL any thoughts on this anybody?

User Image BullRush247 Posted - 23 hours ago

$AUTL the good news here is AUTL didn’t change in price at all since the announcement of delay earnings Which I think is a positive

User Image SouthernItUp Posted - 1 day ago

$AUTL God speed here bulls.

User Image BullRush247 Posted - 1 day ago

$AUTL

User Image schiefe13 Posted - 1 day ago

$AUTL such a shame this is missing out on today’s run bc they can’t get accounting right on the partnership

User Image Stock_Titan Posted - 3 days ago

$AUTL Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress https://www.stocktitan.net/news/AUTL/autolus-therapeutics-to-present-three-clinical-data-updates-on-c8nbnbs57wiy.html

User Image yoter Posted - 3 days ago

$AUTL b/o price could be a min. 2.7 billion. 2B +700M (the cash AUTL has). Stock price for this scenario would be around $10.8 per share. Great upside from the current $4 sp.

User Image yoter Posted - 3 days ago

$AUTL maybe wishful thinking, but delay could be due to a a buyout offer

User Image BullRush247 Posted - 3 days ago

$AUTL something up

User Image Mancunian Posted - 4 days ago

$AUTL Autolus has around $700m in cash….

User Image StephCasi97 Posted - 4 days ago

$AUTL Accounting errors

User Image DonCorleone77 Posted - 4 days ago

$AUTL Autolus Therapeutics announces delay to Q1 earnings release, conference call Autolus Therapeutics intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission later this week with regard to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. Form 12b-25 will allow the Company an automatic extension of five additional calendar days to file the Q1 2024 10-Q which is due on May 15, 2024. In accordance with today's announcement, the Company is canceling its previously announced earnings release and call scheduled for before U.S. market open on May 14, 2024. The Company expects to file the Q1 2024 10-Q as soon as practicable and no later than the May 20, 2024 deadline in compliance with Rule 12b-25. The Company has rescheduled its first quarter 2024 conference call and webcast to now be held on May 17, 2024 at 8:30 am EDT/1:30 pm BST to discuss the Company's financial results and provide a general business update.

User Image aecids Posted - 4 days ago

$AUTL Interesting… https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-delay-its-first-quarter-2024

User Image Stock_Titan Posted - 4 days ago

$AUTL Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call https://www.stocktitan.net/news/AUTL/autolus-therapeutics-announces-delay-to-its-first-quarter-2024-oi1emcevuov0.html

User Image Mancunian Posted - 1 week ago

$AUTL update May 14th..

User Image SouthernItUp Posted - 1 week ago

$AUTL

User Image AlphaTauri Posted - 1 week ago

$AUTL this downtrend is a big buyop for me... this reminds me of $IOVA... down 50% after PDUFA submission (6$ to 3$) before rebouncing 3months before PDUFA. Now in the teens !!!

User Image StephCasi97 Posted - 1 week ago

$AUTL

User Image yoter Posted - 2 weeks ago

$AUTL even if we hear no major news until November, we are in for a x2 increase in sp in anticipation of Nov. 16 FDA decision date. So this recent downtrend is a good opportunity to accumulate. Stay the course Bulls

User Image Magic8BallResponse Posted - 2 weeks ago

$AUTL What a shame.... seems to be down since BionT deal

User Image Mancunian Posted - 2 weeks ago

$AUTL Follow the science and not the daily trading

User Image _www_larval_com_ Posted - 2 weeks ago

$AUTL just shot 3% higher to 6% (~6Mv) moments ago, 05/17 options, follow for more volatility.

Analyst Ratings
Needham Buy Apr 12, 24
Truist Securities Buy Apr 9, 24
Truist Securities Buy Mar 18, 24
Needham Buy Mar 14, 24
Needham Buy Feb 12, 24
Needham Buy Jan 22, 24
Goldman Sachs Neutral Dec 13, 23
Needham Buy Nov 29, 23
Deutsche Bank Buy Nov 9, 23